Nerve disorders are largely divided into brain disorder and spinal cord disorder, and FCB-Pharmicell has both domestic and foreign patents on nerve cell activity technology using stem cells. As part of the next generation growth project of the Ministry of Health and Welfare we are developing drugs for cerebral hemorrhage, brain infarction, Parkinson's disease and traumatic brain disease, and especially received authorization of clinical tests for commercialization of the brain infarction treatment drug from the KFDA in 2005(IND-III). We are preparing for clinical tests for commercialization for spinal cord disorder patients based on our positive clinical spinal disorder drug tests.

Spinal disorder is usually caused by pressure to the spine due to an external injury. It leads to loss autonomic nerve functions which control normal activities, nerves, the bladder and intestines, and leads to paralysis of the entire body or lower half of the body, disabling the patient from living an independent life. Spinal disorders in youths are frequenting currently due to traffic accidents, industrial accidents, and an increase in sports activities and the number of spinal disorder patients is increasing, too. The degree of disabilities due to spine damage are 34.5 percent incomplete whole body paralysis, 23.1 percent complete lower body paralysis, 18.4 percent complete whole body paralysis and 17.5 percent incomplete lower body paralysis and only under 1 percent recover damaged nerves.

Having received an authorization and approval of KFDA, in December 2007, on conducting spinal cord injuries clinical trial phase-II/III for commercial purposes, we are currently conducting the trial at Seoul Asan Hospital since March 2008. We endeavor our time and effort for commercialization of drugs on spinal cord injuries, as it is a terminal disorder with non-existing treatment available yet.